Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in three upcoming investor conferences in May 2025: Bank of America Securities 2025 Health Care Conference on May 13th at 6:40 PM ET H.C.

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in three upcoming investor conferences in May 2025:

• Bank of America Securities 2025 Health Care Conference on May 13th at 6:40 PM ET
• H.C. Wainwright & Co. 3rd Annual BioConnect Nasdaq Investor Conference on May 20th at 3:00 PM ET
• Stifel Virtual Ophthalmology Forum on May 27th at 10:30 AM ET

Live webcasts will be available on the events section of Tarsus's website, with replays accessible within 48 hours and archived for a limited time.

Argus Session date unavailable

-5.05% session move Open Argus

Details

News Market Reaction – TARS

The recorded move for TARS in the trading session of this news was -5.05%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences:

• Bank of America Securities 2025 Health Care Conference on Tuesday, May 13^th, at 3:40 p.m. PT / 6:40 p.m. ET
• H.C. Wainwright & Co. 3^rd Annual BioConnect Nasdaq Investor Conference on Tuesday, May 20^th, at 12:00 p.m. PT / 3:00 p.m. ET
• Stifel Virtual Ophthalmology Forum on Tuesday, May 27^th, at 7:30 a.m. PT / 10:30 a.m. ET
  

Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the prevention of Lyme disease.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor conferences will Tarsus Pharmaceuticals (TARS) attend in May 2025?

Tarsus will participate in three conferences: Bank of America Securities Health Care Conference (May 13), H.C. Wainwright BioConnect Nasdaq Investor Conference (May 20), and Stifel Virtual Ophthalmology Forum (May 27).

When is Tarsus Pharmaceuticals (TARS) presenting at the Bank of America Securities Health Care Conference 2025?

Tarsus will present at the Bank of America Securities Health Care Conference on Tuesday, May 13th, 2025, at 6:40 PM ET.

How can investors access Tarsus Pharmaceuticals' (TARS) conference presentations?

Investors can access live webcasts through the events section of Tarsus's website. Replays will be available within 48 hours and archived for a limited time.

What time is Tarsus (TARS) presenting at the Stifel Virtual Ophthalmology Forum?

Tarsus will present at the Stifel Virtual Ophthalmology Forum on Tuesday, May 27th, 2025, at 10:30 AM ET.